A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Pharmacokinetics, and Safety of CDP870 Without Coadministration of MTX in Japanese Active RA Patients in Whom MTX Cannot be Administered

Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Pharmacokinetics, and Safety of CDP870 Without Coadministration of MTX in Japanese Active RA Patients in Whom MTX Cannot be Administered

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2017

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms HIKARI
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 23 Apr 2015 According to an Astellas Pharma media release, 4-year data from this study were presented at the Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology 2015.
    • 13 Jun 2014 According to the UCB Pharmaceuticals media release, results from this trial presented at the 15th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top